Reduction in caffeine withdrawal after open-label decaffeinated coffee

被引:1
|
作者
Mills, Llewellyn [1 ,2 ]
Lee, Jessica C. [3 ]
Boakes, Robert [4 ]
Colagiuri, Ben [4 ]
机构
[1] Univ Sydney, Cent Clin Sch, Discipline Addict Med, Griffith Taylor Bldg A19,Manning Rd, Sydney, NSW 2006, Australia
[2] South Eastern Sydney Local Hlth Dist, Drug & Alcohol Serv, Sydney, NSW, Australia
[3] Univ New South Wales, Sch Psychol, Sydney, NSW, Australia
[4] Univ Sydney, Sch Psychol, Sydney, NSW, Australia
关键词
Withdrawal; addiction; caffeine; expectancy; placebo; DOUBLE-BLIND; CONDITIONED PLACEBO; SMOKING WITHDRAWAL; SYMPTOMS; ALCOHOL; EXPECTANCY; RELAPSE; DEPENDENCE; ANALGESIA; RESPONSES;
D O I
10.1177/02698811221147152
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Withdrawal from addictive drugs can be reduced by administering placebo deceptively, but in the clinic it is unethical to deceive the patient. Open-label placebo effects have been observed across a range of psychophysiological phenomena, and may also apply to drug withdrawal. Method: 24-hour abstinent heavy coffee drinkers (N = 61) rated their caffeine withdrawal symptoms before being allocated to one of three groups. The Deceptive group was given decaffeinated coffee (decaf) and told it was caffeinated, the Open-Label group given decaf and told it was decaf and the Control group given water and told it was water. After 45 min, caffeine withdrawal was measured again. All participants rated their expectancies of withdrawal reduction from caffeinated coffee, decaf and water prior to being randomised and the end of the study. Results: There was a significant 9.5-point reduction in caffeine withdrawal in the Open-Label group (95% confidence interval (CI): 4.7, 14.3; p = 0.002), which was 8.6 points less than the Deceptive group (95%CI: 0.4, 16.8; p = 0.014) but 8.9 points greater than the Control group (95%CI: 0.6, 17.2; p = 0.012). Pre-randomisation, participants expected caffeinated coffee to reduce their withdrawal symptoms the most, followed by water and decaf, Pre-randomisation expectancy of withdrawal was only associated with amount of withdrawal reduction in the Deceptive group. Conclusion: It appears as if open-label placebo caffeine (i.e. decaf) can reduce caffeine withdrawal symptoms, even when people do not hold a conscious expectancy it will do so. There may be ways to integrate open-label placebo procedures into clinical interventions for drug dependence without violating informed consent.
引用
收藏
页码:181 / 191
页数:11
相关论文
共 50 条
  • [21] Caffeine in Parkinson's disease: A pilot open-label, dose-escalation study
    Altman, Robert D.
    Lang, Anthony E.
    Postuma, Ronald B.
    MOVEMENT DISORDERS, 2011, 26 (13) : 2427 - 2431
  • [22] A prospective, randomized, open-label study of steroid withdrawal in pancreas transplantation (Pa Tx).
    Gruessner, RWG
    Sutherland, DER
    Parr, E
    Humar, A
    Gruessner, AC
    TRANSPLANTATION, 2000, 69 (08) : S408 - S408
  • [23] Caffeinated coffee, decaffeinated coffee, and caffeine in relation to plasma C-pepticle, a marker of insulin secretion, in US women
    Wu, TY
    Hankinson, SE
    Willett, WC
    Giovannucci, E
    CIRCULATION, 2004, 110 (17) : 817 - 818
  • [24] Sarilumab Dose Reduction in an Open-label Extension Study in RA Patients
    Genovese, Mark
    Fay, Jonathan
    Parrino, Janie
    Beyer, Doris
    Iglesias-Rodriguez, Melitza
    van Hoogstraten, Hubert
    Graham, Neil
    Boddy, Alex
    Simon, Abraham
    Martincova, Renata
    Burmester, Gerd
    Fiore, Stefano
    JOURNAL OF RHEUMATOLOGY, 2017, 44 (06) : 895 - 896
  • [25] Sarilumab Dose Reduction in an Open-Label Extension Study in RA Patients
    Genovese, Mark C.
    Fay, Jon
    Parrino, Janie
    Beyer, Doris
    Iglesias-Rodriguez, Melitza
    Graham, Neil
    Boddy, Alex
    Simon, J-Abraham
    Martincova, Renata
    Burmester, Gerd R.
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [26] SARILUMAB DOSE REDUCTION IN AN OPEN-LABEL EXTENSION STUDY IN RA PATIENTS
    Genovese, M. C.
    Fay, J.
    Beyer, D.
    Iglesias-Rodriguez, M.
    Simon, A.
    Martincova, R.
    Burmester, G. R.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2018, 24 : S69 - S70
  • [27] Comparison of capillary electrophoresis and high performance liquid chromatography methods for caffeine determination in decaffeinated coffee
    Bizzotto, Carolina Schaper
    Meinhart, Adriana Dillenburg
    Ballus, Cristiano Augusto
    Ghiselli, Gislaine
    Godoy, Helena Teixeira
    FOOD SCIENCE AND TECHNOLOGY, 2013, 33 (01): : 186 - 191
  • [28] Effect of caffeine-containing versus decaffeinated coffee on serum clozapine concentrations in hospitalised patients
    Raaska, K
    Raitasuo, V
    Laitila, J
    Neuvonen, PJ
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2004, 94 (01) : 13 - 18
  • [29] Continuation, reduction, or withdrawal of tofacitinib in patients with rheumatoid arthritis achieving sustained disease control: a multicenter, open-label, randomized controlled trial
    Wang Mengyan
    Xue Yu
    Du Fang
    Ma Lili
    Lu Liang-jing
    Jiang Lindi
    Tao Yi-Li
    Yang Chengde
    Shi Hui
    Liu Honglei
    Cheng Xiaobing
    Ye Junna
    Su Yutong
    Zhao Dongbao
    Dai Sheng-Ming
    Teng Jialin
    Hu Qiongyi
    中华医学杂志英文版, 2023, 136 (03)
  • [30] Continuation, reduction, or withdrawal of tofacitinib in patients with rheumatoid arthritis achieving sustained disease control: a multicenter, open-label, randomized controlled trial
    Wang, Mengyan
    Xue, Yu
    Du, Fang
    Ma, Lili
    Lu, Liang-jing
    Jiang, Lindi
    Tao, Yi-Li
    Yang, Chengde
    Shi, Hui
    Liu, Honglei
    Cheng, Xiaobing
    Ye, Junna
    Su, Yutong
    Zhao, Dongbao
    Dai, Sheng-Ming
    Teng, Jialin
    Hu, Qiongyi
    CHINESE MEDICAL JOURNAL, 2023, 136 (03) : 331 - 340